You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Contact a GSK Sales Representative

Chat with Medical Information

BEXSERO: Demonstrated Impact of Vaccination on Disease Incidence

BEXSERO data from a Quebec immunization campaign (2014 to 2018) 1

The hyper-endemic serogroup B strain ST-269 emerged in the province of Quebec in 2003 and attributed to a steadily increasing incidence of serogroup B IMD with the Saguenay-Lac-Saint-Jean (SLSJ) region having the greatest incidence rates in Quebec.

A short-term mass immunization campaign was initiated in May 2014 with BEXSERO, targeting individuals between 2 months to 20 years of age residing or attending school in SLSJ.

The disease incidence in SLSJ from 2014 to 2018 decreased in the targeted age group.

BEXSERO UK data from a National Immunization Program (NIP) September 2015 to August 2018 1

In the UK, a national immunization program with BEXSERO was initiated in September 2015 using a two-dose schedule in infants (at 2 and 4 months of age) followed by a booster (at 12 months of age), resulting in 88%-96% of 1,950,000 infants vaccinated with BEXSERO. Public Health England conducted a 3-year observational study at the national level covering the entire birth cohort from September 2015 to August 2018. Consistently high uptake was observed throughout the program (92.5% vaccinated by first birthday, 87.9% received all 3 doses by 2 years).

After three years of the program, a reduction of 75% [Incidence Rate Ratio 0.25 (95% CI: 0.19; 0.36)] in IMD caused by Neisseria meningitidis group B was observed in vaccine-eligible infants, irrespective of the infants’ vaccination status or predicted meningococcal group B strain coverage.

See the full study, published in 2020 in the New England Journal of Medicine

Reference:

  1. BEXSERO Product Monograph. November 9, 2023.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit our consumer website BEXSERO.ca.

Français